Ventyx Won’t Pursue Psoriasis Further Despite Phase II Success

Ventyx Biosciences, Inc. provided a disappointing update to shareholders on 6 November, revealing that despite meeting primary and secondary endpoints in a Phase II trial in plaque psoriasis, it is ending development of VTX958 in both psoriasis and psoriatic arthritis because the profile will not be competitive with Bristol Myers Squibb Company’s Sotyktu and other investigational TYK2 inhibitors. A Phase II study in Crohn’s disease will continue, with an interim efficacy analysis planned during the first quarter of 2024, the company told an investor call.